Content Type: Commentary & Opinion

Legal Challenges to State Drug Pricing Laws

March 16, 2026

The Trans-Pacific Partnership Agreement and Implications for Access to Essential Medicines

March 16, 2026

Recent Orange and Purple Book Legislation Suggests a Need to Bridge Drug and Biologic Patent Regimes

March 16, 2026

The Future of Drug-Pricing Transparency

March 16, 2026

State Initiatives to Control Medication Costs—Can Transparency Legislation Help?

March 16, 2026

Active Surveillance of Follow-On Biologics: A Prescription for Uptake

March 16, 2026

Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?

March 16, 2026

Lifecycle Regulation of Artificial Intelligence- and Machine Learning-Based Software Devices in Medicine

March 16, 2026

The US Food and Drug Administration 515 Program Initiative: Addressing the Evidence Gap for Widely Used, High-Risk Cardiovascular Devices?

March 16, 2026

Covert Pharmaceutical Promotion in Free Medical Journals

March 16, 2026

Variability in Global Drug Prices

March 16, 2026

Aducanumab and Accelerated Approval: Where Do We Go From Here?

March 16, 2026